MARKET COMPOSITE
BCRX - Biocryst Pharmaceuticals Inc.8:00:00 PM 3/27/2024
Price
$5.15
+ 0.14 (2.79%)
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug RAPIVAB was approved by FDA in Dec 2014. It has also been approved in Japan, Korea and China The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
Financials
Quarterly financials
(USD)Dec 2023Q/Q
Revenue93.4MM+8%
Gross Profit91.8MM-
Cost Of Revenue1.6MM+42%
Operating Income-42.7MM-
Operating Expenses134.5MM-
Net Income-61.7MM+71%
R&D70.1MM+49%
G&A64.4MM+27%
Interest Expense24.6MM-10%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m. ET. Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media s

    In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]

    RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees stock options to purchase an aggregate of 16,050 shares, and restricted stock units (RSUs) covering an aggregate of 11,300 shares, of BioCryst common stock. The options and RSUs were granted as of February 29, 2024, as inducements material to each employee entering into e

    Each of these hidden penny stock gems have the potential to provide triple digit growth to investors. Investors are forever on the lookout for Investments that can turn $1 into $2 or more. That is precisely the potential that the stocks below offer to investors. The firms discussed below are also relatively unknown and are generally not household names. They can therefore be characterized as hidden gems given their strong potential upside. As always, invest in penny stocks what you are willing t

    BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript February 26, 2024 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.28 EPS, expectations were $-0.24. BioCryst Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]

    BioCryst Pharmaceuticals ( NASDAQ:BCRX ) Full Year 2023 Results Key Financial Results Revenue: US$331.4m (up 22% from...

    Q4 2023 BioCryst Pharmaceuticals Inc Earnings Call

    BCRX earnings call for the period ending December 31, 2023.

    BioCryst (BCRX) delivered earnings and revenue surprises of -16.67% and 4.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

    BCRX Announces Q4 and Full Year 2023 Financial Results with a Positive Outlook for the Coming Years